Cost-effectiveness analysis of systemic therapy for non-small cell lung cancer based on real-world data
Not Applicable
Recruiting
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000052124
- Lead Sponsor
- Showa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with the following driver gene mutations or translocations will be included: EGFR gene mutation ALK fusion gene ROS1 fusion gene BRAF gene mutation MET gene mutation RET fusion gene NTRK fusion gene In the future, if new primary standard treatments are identified for additional driver gene mutations or translocations, patients with those newly identified driver gene mutations or translocations will also be excluded from the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method From the initiation of anticancer drug treatment following fulfillment of inclusion criteria until the date of death, the incremental cost-effectiveness ratios (ICERs) for the four groups, namely B to E, relative to the base case A, are as follows: A. Cytotoxic anticancer agent B. Platinum combination therapy + PD-1/PD-L1 inhibitor C. Platinum combination therapy + PD-1 inhibitor + CTLA-4 inhibitor D. PD-1 inhibitor + CTLA-4 inhibitor E. PD-1/PD-L1 inhibitor We will evaluate and compare the ICERAB, ICERAC, ICERAD, and ICERAE to assess the cost-effectiveness of these different therapeutic approaches for the specified patient population.
- Secondary Outcome Measures
Name Time Method